Drug eruptions in posterior spinal fusion for adolescent idiopathic scoliosis

Objective: An important issue in adolescent idiopathic scoliosis (AIS) correction surgery is postoperative pain management due to the procedure's relatively high invasiveness. Although celecoxib is widely used as an analgesic for post-surgical pain, there have been several reports of drug eruptions. Such side effects may similarly occur in AIS patients following posterior spinal fusion (PSF). However, no studies have specifically addressed perioperative rash from analgesics in scoliosis surgery. We investigated the incidence of drug eruptions in PSF for AIS and their patient-related risk factors. Methods: We retrospectively reviewed the medical records of 134 consecutive patients who underwent PSF for AIS. Sixty-six patients had received celecoxib and 68 had taken NSAIDs, acetaminophen, or other painkillers after surgery. We investigated the incidence of drug eruptions between patients who took celecoxib (celecoxib group) or other painkillers (others group) and searched for factors associated with rash after surgery by means of a logistic regression model. Results: The overall incidence of drug eruptions after PSF for AIS was 11.9%. The incidence of eruptions in the celecoxib group (18.2%) was significantly higher than in the others group (5.9%) (p = 0.034). The patient -related factors of celecoxib intake and allergic history had significant associations with drug eruptions in multivariate analysis, with odds ratios of 3.88 and 3.53, respectively. Conclusion: In PSF surgery for AIS, patients who receive celecoxib and/or have a history of allergies are signif-icantly more likely to exhibit a rash and should be observed closely for drug eruptions.